Quidel to Present at Cowen 33rd Annual Health Care Conference
February 25 2013 - 4:30PM
Marketwired
Quidel Corporation (NASDAQ: QDEL), a leading
provider of rapid diagnostic testing solutions and cellular-based
virology assays, announced today that it will present at the Cowen
and Company 33rd Annual Health Care Conference to be held at the
Boston Marriott Copley Place hotel in Boston, Massachusetts on
Tuesday, March 5, 2013.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 9:20
a.m. Eastern time (6:20 a.m. Pacific time) with a question and
answer session scheduled immediately following the presentation.
During the presentation, the company will discuss business and
financial developments and trends. The company's statements may
contain or constitute material information that has not been
previously disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company's Web
site at www.quidel.com. Participants should allow approximately
five to ten minutes prior to the presentation's start time to visit
the site and download any streaming media software needed to listen
to the Internet webcast. A replay of the webcast will also be
available on the company's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
QuickVue®, D3® Direct Detection and Thyretain® leading brand names,
as well as under the new Sofia® and AmpliVue® brands, Quidel's
products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's research and development
engine is also developing a continuum of diagnostic solutions from
advanced lateral-flow and direct fluorescent antibody to molecular
diagnostic tests to further improve the quality of healthcare in
physicians' offices and hospital and reference laboratories. For
more information about Quidel's comprehensive product portfolio,
visit www.quidel.com and Diagnostic Hybrids at www.dhiusa.com.
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931 Media and Investors Contact: Quidel
Corporation Ruben Argueta (858) 646-8023 Email Contact
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024